Jubilant Life shares end nearly 9% up on USFDA nod for drug

Shares of Jubilant Life Sciences ended with nearly 9 per cent gains today as the company received final approval from the US health regulator for its generic version of anti-depressant Paxil tablets.
The stock soared 8.67 per cent to settle at Rs 447.95 on BSE. During the day, it surged 10.14 per cent to Rs 454 - its 52-week high.
At NSE, shares of the company jumped 8.19 per cent to end at Rs 448.10.
The company's market valuation rose by Rs 570 crore to Rs 7,135 crore.
On the volume front, 8.85 lakh shares of the company changed hands at BSE and over 33 lakh shares were traded at NSE during the day.

The final approval for the abbreviated new drug application (ANDA) from the US Food and Drug Administration (USFDA) for Paroxetine tablets of Apotex is for the strengths of 10 mg, 20 mg, 30 mg and 40 mg, the company said in a BSE filing today.
As on September 30, 2015, Jubilant Life Sciences had a total of 820 filings for formulations, of which 391 have been approved in various regions globally.
These include 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe, it said.